CY1124828T1 - Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης - Google Patents
Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινηςInfo
- Publication number
- CY1124828T1 CY1124828T1 CY20211101106T CY211101106T CY1124828T1 CY 1124828 T1 CY1124828 T1 CY 1124828T1 CY 20211101106 T CY20211101106 T CY 20211101106T CY 211101106 T CY211101106 T CY 211101106T CY 1124828 T1 CY1124828 T1 CY 1124828T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- compounds
- allosteric modulators
- acetylcholine receptors
- nicotine acetylcholine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Η παρούσα αποκάλυψη σχετίζεται με ενώσεις του χημικού τύπου (Ι) που είναι χρήσιμες ως διαμορφωτές του α7 nAChR, συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις, και τη χρήση τέτοιων ενώσεων για πρόληψη, αγωγή, ή βελτίωση πάθησης, ειδικότερα διαταραχών του κεντρικού νευρικού συστήματος όπως είναι οι γνωσιακές εξασθενίσεις σε νόσο του Αλτσχάιμερ, νόσο του Πάρκινσον, και σχιζοφρένεια, ως επίσης και για επαγόμενη από L-DOPA δυσκινησία και φλεγμονή.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662311888P | 2016-03-22 | 2016-03-22 | |
US201662369778P | 2016-08-02 | 2016-08-02 | |
PCT/US2017/023127 WO2017165256A1 (en) | 2016-03-22 | 2017-03-20 | Allosteric modulators of nicotinic acetylcholine receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124828T1 true CY1124828T1 (el) | 2022-11-25 |
Family
ID=58455680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211101106T CY1124828T1 (el) | 2016-03-22 | 2021-12-16 | Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης |
Country Status (39)
Country | Link |
---|---|
US (3) | US9840481B2 (el) |
EP (2) | EP3978479A1 (el) |
JP (1) | JP6526352B2 (el) |
KR (1) | KR102203552B1 (el) |
CN (1) | CN109153649B (el) |
AR (1) | AR107928A1 (el) |
AU (1) | AU2017237930B2 (el) |
CA (1) | CA3018185C (el) |
CL (1) | CL2018002697A1 (el) |
CO (1) | CO2018009889A2 (el) |
CR (1) | CR20180452A (el) |
CY (1) | CY1124828T1 (el) |
DK (1) | DK3433234T3 (el) |
DO (1) | DOP2018000204A (el) |
EC (1) | ECSP18078877A (el) |
ES (1) | ES2901197T3 (el) |
GE (1) | GEP20207149B (el) |
HR (1) | HRP20211960T1 (el) |
HU (1) | HUE057460T2 (el) |
IL (1) | IL261807A (el) |
JO (1) | JOP20170067B1 (el) |
LT (1) | LT3433234T (el) |
MA (1) | MA43756B1 (el) |
MD (1) | MD3433234T2 (el) |
MX (1) | MX2018011453A (el) |
MY (1) | MY195948A (el) |
PE (1) | PE20181851A1 (el) |
PH (1) | PH12018502028A1 (el) |
PL (1) | PL3433234T3 (el) |
PT (1) | PT3433234T (el) |
RS (1) | RS62704B1 (el) |
SG (1) | SG11201808220VA (el) |
SI (1) | SI3433234T1 (el) |
SV (1) | SV2018005743A (el) |
TN (1) | TN2018000322A1 (el) |
TW (1) | TWI616438B (el) |
UA (1) | UA120571C2 (el) |
WO (1) | WO2017165256A1 (el) |
ZA (1) | ZA201806141B (el) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102657259B1 (ko) | 2015-04-17 | 2024-04-16 | 코르테바 애그리사이언스 엘엘씨 | 살충 유용성을 갖는 분자, 및 그와 관련된 중간체, 조성물 및 방법 |
NZ753358A (en) | 2016-10-12 | 2022-07-29 | Corteva Agriscience Llc | Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto |
JP7041141B2 (ja) * | 2016-11-01 | 2022-03-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換された二環式ヘテロアリール系ニコチン性アセチルコリン受容体アロステリック調節剤 |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
WO2019000238A1 (en) * | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
EP3684357B1 (en) * | 2017-09-19 | 2022-12-28 | Merck Sharp & Dohme LLC | Heteroaryl allosteric modulators of nicotinic acetylcholine receptors |
CR20200509A (es) * | 2018-05-01 | 2020-12-23 | Merck Sharp & Dohme | Moduladores alostéricos de espiropiperidina receptores nicotínicos de acetilcolina |
HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
HU231414B1 (hu) * | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
TW202039420A (zh) * | 2018-11-26 | 2020-11-01 | 美商富曼西公司 | 用於防治無脊椎害蟲的間二醯胺化合物 |
US20220119351A1 (en) * | 2019-05-02 | 2022-04-21 | Merck Sharp & Dohme Corp. | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
EP4054569A4 (en) * | 2019-11-05 | 2023-10-25 | Merck Sharp & Dohme LLC | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS |
CN111233783B (zh) * | 2020-03-13 | 2021-11-16 | 温州大学 | 异噻唑-4-基二硫化物衍生物的合成方法 |
WO2023049058A1 (en) * | 2021-09-21 | 2023-03-30 | Merck Sharp & Dohme Llc | Allosteric modulators of nicotinic acetylcholine receptors |
WO2023064771A1 (en) * | 2021-10-12 | 2023-04-20 | Brown University | Glioblastoma multiforme treatments |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3487154A (en) | 1967-04-03 | 1969-12-30 | Smithkline Corp | Method of lowering blood pressure |
US3522302A (en) | 1967-05-16 | 1970-07-28 | Smithkline Corp | P-(2-aminocycloalkyl)benzenesulfonamides |
FR2508033A1 (fr) | 1981-06-23 | 1982-12-24 | Fabre Sa Pierre | Aryl-1 aminomethyl-2 cyclopropanes carboxylates (z), leur preparation et leur application en tant que medicaments utiles dans le traitement d'algies diverses |
US5286736A (en) | 1990-11-22 | 1994-02-15 | Dr. Karl Thomae Gmbh | Pyridyl compounds and pharmaceutical compositions containing these compounds |
TW394761B (en) | 1993-06-28 | 2000-06-21 | Hoffmann La Roche | Novel Sulfonylamino Pyrimidines |
FR2751645B1 (fr) | 1996-07-29 | 1998-12-24 | Sanofi Sa | Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales |
AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
DE69905451T2 (de) | 1998-02-17 | 2003-11-20 | Astrazeneca Uk Ltd | Neue triazolo(4,5d) pyrimidinverbindungen |
SE9802574D0 (sv) | 1998-07-17 | 1998-07-17 | Astra Pharma Prod | Novel compounds |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
KR20020070385A (ko) | 2000-01-29 | 2002-09-06 | 주식회사 엘지씨아이 | 아릴-아미딘을 가진 팩터 Xa 억제제와 그의 유도체, 및그의 프로드럭 |
US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
FR2810664B1 (fr) * | 2000-06-27 | 2004-12-24 | Adir | Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6777437B2 (en) | 2001-03-29 | 2004-08-17 | Bristol-Myers Squibb Company | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
ES2362656T3 (es) | 2003-01-06 | 2011-07-11 | Eli Lilly And Company | Arilciclopropilacetamidas sustituidas como activadores de glucoquinasa. |
EP1833804A1 (en) * | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
JP2009506063A (ja) * | 2005-08-24 | 2009-02-12 | リブ−エックス ファーマシューティカルズ,インコーポレイテッド | トリアゾール化合物ならびにこれを作製する方法および使用する方法 |
US20080255069A1 (en) | 2005-09-09 | 2008-10-16 | R & R Inc. | Medicament for Preventive and/or Therapeutic Treatment of Bowel Disease |
MX2010003155A (es) * | 2007-10-04 | 2010-04-01 | Hoffmann La Roche | Derivados de ciclopropil aril amida y uso de los mismos. |
CA2707789A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Phenyl acetic acid derivatives as inflammation modulators |
EP2219646A4 (en) | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
KR101333401B1 (ko) | 2008-08-12 | 2013-11-28 | 에프. 호프만-라 로슈 아게 | 니코틴성 알파 7 조절제로서 살리실아미드 유도체 |
PE20120061A1 (es) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | Derivados de pirimidina como antagonistas del receptor ccr2 |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
JP5530514B2 (ja) | 2009-06-11 | 2014-06-25 | アッヴィ・バハマズ・リミテッド | Hcv感染を治療するための抗ウィルス化合物 |
WO2010144959A1 (en) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
US8552022B2 (en) | 2009-08-13 | 2013-10-08 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
US9303027B2 (en) | 2010-07-19 | 2016-04-05 | Dr. Reddy's Laboratories Ltd. | Kappa opioid receptor agonists |
WO2012047852A2 (en) | 2010-10-07 | 2012-04-12 | The J. David Gladstone Institutes | Compositions and methods for modulating immunodeficiency virus transcription |
MX2013006951A (es) | 2010-12-16 | 2013-10-03 | Abbvie Inc | Compuestos antivirales. |
KR101925971B1 (ko) | 2011-01-28 | 2018-12-06 | 에스케이바이오팜 주식회사 | 피리돈 유도체 및 이를 포함하는 약학적 조성물 |
US9062013B2 (en) | 2011-02-02 | 2015-06-23 | Bionomics Limited | Positive allosteric modulators of the α7 nicotinic acetylcholine receptor and uses thereof |
RS55433B1 (sr) * | 2011-02-23 | 2017-04-28 | Lupin Ltd | Derivati heteroarila kao modulatori nachr alfa7 |
US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
WO2013005153A1 (en) * | 2011-07-05 | 2013-01-10 | Lupin Limited | Biaryl derivatives as nachr modulators |
US8598213B2 (en) | 2011-07-08 | 2013-12-03 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
UA111746C2 (uk) | 2011-07-08 | 2016-06-10 | Х. Луннбек А/С | Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну |
CA2844469C (en) | 2011-08-08 | 2019-08-20 | Merck Patent Gmbh | N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists |
WO2014006120A1 (en) | 2012-07-06 | 2014-01-09 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
KR20150036766A (ko) * | 2012-08-01 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | α7 니코틴성 아세틸콜린 수용체 조절제 및 그의 용도-I |
US20150315130A1 (en) | 2012-12-10 | 2015-11-05 | H. Lundbeck A/S | New positive allosteric modulators of nicotinic acetylcholine receptor |
PT2968440T (pt) | 2013-03-15 | 2019-07-31 | Zymeworks Inc | Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos |
WO2014172759A1 (en) | 2013-04-24 | 2014-10-30 | Bionomics Limited | α7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF - III |
TW201446243A (zh) * | 2013-06-03 | 2014-12-16 | Lupin Ltd | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |
ES2916722T3 (es) | 2013-12-27 | 2022-07-05 | Zymeworks Inc | Sistemas de enlace que contienen sulfonamida para conjugados de fármacos |
MX2016008448A (es) | 2013-12-27 | 2017-01-09 | Zymeworks Inc | Conjugados de var2csa-farmaco. |
US10179790B2 (en) | 2014-06-04 | 2019-01-15 | Thomas Helledays Stiftelse For Medicinsk Forskning | MTH1 inhibitors for treatment of cancer |
SG11201609981RA (en) | 2014-06-04 | 2016-12-29 | Thomas Helledays Stiftelse För Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
WO2015191799A1 (en) * | 2014-06-13 | 2015-12-17 | Merck Sharp & Dohme Corp. | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof |
-
2017
- 2017-03-20 US US15/463,336 patent/US9840481B2/en active Active
- 2017-03-20 TN TNP/2018/000322A patent/TN2018000322A1/en unknown
- 2017-03-20 US US16/087,382 patent/US20190337910A1/en not_active Abandoned
- 2017-03-20 DK DK17714623.0T patent/DK3433234T3/da active
- 2017-03-20 MX MX2018011453A patent/MX2018011453A/es active IP Right Grant
- 2017-03-20 JP JP2018549170A patent/JP6526352B2/ja active Active
- 2017-03-20 LT LTEPPCT/US2017/023127T patent/LT3433234T/lt unknown
- 2017-03-20 CN CN201780031228.9A patent/CN109153649B/zh active Active
- 2017-03-20 MA MA43756A patent/MA43756B1/fr unknown
- 2017-03-20 PE PE2018001841A patent/PE20181851A1/es unknown
- 2017-03-20 HU HUE17714623A patent/HUE057460T2/hu unknown
- 2017-03-20 SI SI201730988T patent/SI3433234T1/sl unknown
- 2017-03-20 JO JOP/2017/0067A patent/JOP20170067B1/ar active
- 2017-03-20 WO PCT/US2017/023127 patent/WO2017165256A1/en active Application Filing
- 2017-03-20 RS RS20211533A patent/RS62704B1/sr unknown
- 2017-03-20 UA UAA201809635A patent/UA120571C2/uk unknown
- 2017-03-20 TW TW106109075A patent/TWI616438B/zh active
- 2017-03-20 EP EP21204099.2A patent/EP3978479A1/en not_active Withdrawn
- 2017-03-20 PT PT177146230T patent/PT3433234T/pt unknown
- 2017-03-20 CR CR20180452A patent/CR20180452A/es unknown
- 2017-03-20 EP EP17714623.0A patent/EP3433234B1/en active Active
- 2017-03-20 SG SG11201808220VA patent/SG11201808220VA/en unknown
- 2017-03-20 GE GEAP201714908A patent/GEP20207149B/en unknown
- 2017-03-20 HR HRP20211960TT patent/HRP20211960T1/hr unknown
- 2017-03-20 AU AU2017237930A patent/AU2017237930B2/en active Active
- 2017-03-20 AR ARP170100686A patent/AR107928A1/es unknown
- 2017-03-20 MY MYPI2018001607A patent/MY195948A/en unknown
- 2017-03-20 PL PL17714623T patent/PL3433234T3/pl unknown
- 2017-03-20 MD MDE20190130T patent/MD3433234T2/ro unknown
- 2017-03-20 CA CA3018185A patent/CA3018185C/en active Active
- 2017-03-20 ES ES17714623T patent/ES2901197T3/es active Active
- 2017-03-20 KR KR1020187029892A patent/KR102203552B1/ko active IP Right Grant
- 2017-10-09 US US15/727,982 patent/US9926285B2/en active Active
-
2018
- 2018-09-13 ZA ZA2018/06141A patent/ZA201806141B/en unknown
- 2018-09-16 IL IL261807A patent/IL261807A/en active IP Right Grant
- 2018-09-19 CO CONC2018/0009889A patent/CO2018009889A2/es unknown
- 2018-09-19 SV SV2018005743A patent/SV2018005743A/es unknown
- 2018-09-21 CL CL2018002697A patent/CL2018002697A1/es unknown
- 2018-09-21 DO DO2018000204A patent/DOP2018000204A/es unknown
- 2018-09-21 PH PH12018502028A patent/PH12018502028A1/en unknown
- 2018-10-19 EC ECSENADI201878877A patent/ECSP18078877A/es unknown
-
2021
- 2021-12-16 CY CY20211101106T patent/CY1124828T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124828T1 (el) | Αλλοστερικοι διαμορφωτες των νικοτινικων υποδοχεων ακετυλχολινης | |
CY1124113T1 (el) | Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς | |
NZ768368A (en) | Modulators of cystic fibrosis transmembrane conductance regulator | |
ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
CY1122601T1 (el) | Αναστολεις gsk3 και μεθοδοι χρησης αυτων | |
CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
CY1120846T1 (el) | 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1 | |
UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
CY1121650T1 (el) | Αναστολεις συνθασης αλδοστερονης | |
EA201692260A1 (ru) | Соединения 1,3,4-тиадиазола и их применение в лечении рака | |
CY1121898T1 (el) | Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4 | |
EA202090414A1 (ru) | Соединения и их применение | |
EA202092608A1 (ru) | Спиропиперидиновые аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
EA201792594A1 (ru) | Положительные аллостерические модуляторы мусаринового рецептора м1 | |
PH12019500198A1 (en) | Compounds and compositions and uses thereof | |
EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
CL2017002651A1 (es) | Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer | |
EA201691252A1 (ru) | Соединения индазола в качестве агонистов 5-ht-рецептора | |
EA201892113A1 (ru) | Аллостерические модуляторы никотиновых ацетилхолиновых рецепторов | |
EA201892188A1 (ru) | Соединения пирролотриазина в качестве ингибиторов tam |